Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)

被引：0
|
作者：
Passalacqua, R.
Buzio, C.
Buti, S.
Labianca, R.
Porta, C.
Boni, C.
Rondini, E.
Camisa, R.
Sabbatini, R.
Artioli, F.
Caminiti, C.
机构：
[1] Ist Ospitalieri, Cremona, Italy
[2] Univ Parma, Parma, Italy
[3] Bergamo Hosp, Bergamo, Italy
[4] Policlin San Matteo, Pavia, Italy
[5] Arcispedale S Maria Nuova, Reggio Emilia, Italy
[6] Univ Hosp, Parma, Italy
[7] Univ Hosp, Modena, Italy
[8] Hosp Carpi, Carpi, MO, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA5028
引用
收藏
页数：1
相关论文
共 42 条
  • [31] Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
    Gollob, JA
    Veenstra, KG
    Parker, RA
    Mier, JW
    McDermott, DF
    Clancy, D
    Tutin, L
    Koon, H
    Atkins, MB
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) : 2564 - 2573
  • [32] CLINICAL AND IMMUNOMODULATORY EFFECTS OF COMBINATION IMMUNOTHERAPY WITH LOW-DOSE INTERLEUKIN-2 AND TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER - A PHASE-I TRIAL
    YANG, SC
    GRIMM, EA
    PARKINSON, DR
    CARINHAS, J
    FRY, KD
    MENDIGURENRODRIGUEZ, A
    LICCIARDELLO, J
    OWENSCHAUB, LB
    HONG, WK
    ROTH, JA
    CANCER RESEARCH, 1991, 51 (14) : 3669 - 3676
  • [33] Hydroxyurea (HU), high dose folinic acid (L-FA) and 5FU VS HU, 5FU and interferon-alfa-2b (IFN) in advanced colorectal cancer (ACRC): A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)
    DiCostanzo, F
    Sdrobolini, A
    Marzola, S
    Zironi, S
    Contu, A
    Pucci, E
    Rodino, C
    Corgna, E
    Algeri, R
    Bisagni, G
    Angiona, S
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 721 - 721
  • [34] Phase II trial of the anti-prostate specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 plus low-dose interleukin-2 (IL-2) in patients (pts) with recurrent prostate cancer (PC)
    Jeske, S. J.
    Milowsky, M. I.
    Smith, C. R.
    Smith, K. A.
    Bander, N. H.
    Nanus, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Prospective Randomized Multicenter Adjuvant Dermatologic Cooperative Oncology Group Trial of Low-Dose Interferon Alfa-2b With or Without a Modified High-Dose Interferon Alfa-2b Induction Phase in Patients With Lymph Node-Negative Melanoma
    Hauschild, Axel
    Weichenthal, Michael
    Rass, Knuth
    Linse, Ruthild
    Ulrich, Jens
    Stadler, Rudolf
    Volkenandt, Matthias
    Grabbe, Stephan
    Proske, Ulrike
    Schadendorf, Dirk
    Brockmeyer, Norbert
    Vogt, Thomas
    Rompel, Rainer
    Kaufmann, Roland
    Kaatz, Martin
    Naeher, Helmut
    Mohr, Peter
    Eigentler, Thomas
    Livingstone, Elisabeth
    Garbe, Claus
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3496 - 3502
  • [36] Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma-An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
    Flaherty, Lawrence E.
    Othus, Megan
    Atkins, Michael B.
    Tuthill, Ralph J.
    Thompson, John A.
    Vetto, John T.
    Haluska, Frank G.
    Pappo, Alberto S.
    Sosman, Jeffrey A.
    Redman, Bruce G.
    Moon, James
    Ribas, Antoni
    Kirkwood, John M.
    Sondak, Vernon K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) : 3771 - +
  • [37] Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a Phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial
    Aitchison, M.
    Bray, C. A.
    Van Poppel, H.
    Sylvester, R.
    Graham, J.
    Innes, C.
    McMahon, L.
    Vasey, P. A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 70 - 77
  • [38] Maintenance immunotherapy with low-dose of interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) in patients with metastatic colorectal cancer (MCRC) showing a clinical benefit (CB) from chemotherapy. results of a multicenter phase II study
    Recchia, F.
    Saggio, G.
    Amiconi, G.
    Di Blasio, A.
    Cesta, A.
    Candeloro, G.
    Nuzzo, A.
    Lalli, A.
    Lombardo, M.
    Rea, S.
    ANNALS OF ONCOLOGY, 2006, 17 : 77 - 77
  • [39] Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: A randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma
    Smith, JW
    Kurt, RA
    Baher, AG
    Denman, S
    Justice, L
    Doran, T
    Gilbert, T
    Alvord, WG
    Urba, WJ
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (02): : 130 - 138
  • [40] Low dose interferon-α2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC).: Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS).: A phase III study of the Eastern Cooperative Oncology Group (E2898).
    Gordon, MS
    Manola, J
    Fairclough, D
    Cella, D
    Richardson, R
    Sosman, J
    Kasimis, B
    Dutcher, JP
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 386S - 386S
12345